Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 23.91
- Piotroski Score 7.00
- Grade Buy
- Symbol (PTGX)
- Company Protagonist Therapeutics, Inc.
- Price $46.41
- Changes Percentage (-0.75%)
- Change -$0.35
- Day Low $46.41
- Day High $47.31
- Year High $48.89
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/06/2024
- Fiscal Year End N/A
- Average Stock Price Target $50.00
- High Stock Price Target $50.00
- Low Stock Price Target $50.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $2.54
- Trailing P/E Ratio 13.7
- Forward P/E Ratio 13.7
- P/E Growth 13.7
- Net Income $-78,955,000
Income Statement
Quarterly
Annual
Latest News of PTGX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Is Protagonist Therapeutics, Inc. (PTGX) a Good Healthcare Stock to Buy?
A list of the top 10 healthcare stocks under $50 was recently compiled, with a focus on Protagonist Therapeutics, Inc. and its potential. The healthcare sector shows promise for steady growth, with a ...
By Yahoo! Finance | 4 months ago -
We Think Some Shareholders May Hesitate To Increase Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Compensation
Protagonist Therapeutics' EPS has grown by 26% in the past three years, but shareholders suffered a 21% loss. Concerns about the share price not reflecting the positive EPS growth may be raised at the...
By Yahoo! Finance | 4 months ago
